Volume 4, Issue 6
Editorialp. 481–482
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Author(s): Aaron R Hansen, Albiruni RA Razak
Editorialp. 483–486
How can we manage resistance to antiangiogenic drugs?
Author(s): Dai Chu Luu, Joseph Chao
Editorialp. 487–489
The novel approaches to the treatment of eosinophilic granulomatosis with polyangitis
Author(s): Nobuyuki Miyasaka
News and Viewsp. 491–493
News: Non-small-cell lung cancer in the elderly: updated expert opinion published
Research Updatep. 495–499
The American Lung Association: Asthma Clinical Research Centers network: addressing real life questions in asthma management
Author(s): Elizabeth A Lancet, Janet T Holbrook, Robert A Wise & Nicola A Hanania
Conference Reportp. 501–505
Pathway to improved data management in clinical trials
Author(s): Wolfgang Kuchinke & Toresin Karakoyun
Commentaryp. 507–510
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design
Author(s): Graham W Warren
Review: Clinical Trail Outcomesp. 511–533
Dual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of the latest clinical data
Author(s): Donald Banerji, Robert Fogel & Kai-Michael Beeh
Review: Clinical Trail Outcomesp. 535–548
Bevacizumab in the treatment of epithelial ovarian carcinoma
Author(s): Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomesp. 549–554
Dextromethorphan/quinidine for pseudobulbar affect
Author(s): Steven L Dubovsky
Review: Clinical Trail Outcomesp. 555–565
Ivabradine for the treatment of heart failure
Author(s): Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomesp. 567–584
Agalsidase alfa for the treatment of fabry disease: a closer look
Author(s): Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
